Why did CureVac terminate the development of COVID-19 mRNA vaccine?
- The first Alzheimer’s disease Aβ and Tau pathological surrounding cell structure and gene expression map
- Magic TCR-T cell therapy: 72% of tumor lesions disappeared
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
Another pharmaceutical company gave up its first-generation COVID-19 vaccine research and development! Bayer, CureVac terminate the COVID-19 vaccine
CureVac announced the abandonment of the COVID-19 mRNA vaccine research and development, and the focus of subsequent development shifts to the second-generation vaccine.
On October 12, CureVac announced the withdrawal of its first-generation COVID-19 vaccine candidate CVnCoV from the EMA approval process. This decision also means that the company’s previous 405 million dose vaccine pre-purchase agreement with the European Commission will be terminated.
Prior to August, CureVac and GlaxoSmithKline announced preclinical data on the immune response. The data showed that compared with the first-generation candidate vaccine CVnCoV, the second-generation vaccine candidate CV2CoV better activated the innate and adaptive immune response. , So as to start the immune response faster, and have a higher antibody titer and stronger memory B cell and T cell activation effect.
The company expects to advance the second-generation mRNA vaccine to late-stage clinical practice in the first half of 2022, and seek regulatory approval in the same year.
On September 28, the French pharmaceutical giant Sanofi announced that it would stop the third phase of the messenger ribonucleic acid COVID-19 vaccine. The reason is that the vaccine has missed the best time to market. The company said that it will continue to promote the recombinant protein COVID-19 vaccine. Research and development work.
Bayer AG recently stated that it has terminated a vaccine production partnership under which Bayer will help CureVac produce its COVID-19 vaccine.
Why did CureVac terminate the development of COVID-19 mRNA vaccine?
(source:internet, reference only)
Disclaimer of medicaltrend.org
